Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cameron

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Journal of the National Cancer Institute|October 18, 2024
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysisPer Karlsson, Anthony Fyles, S Laura Chang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO StudyNicholas C Turner, Judith Balmaña, Coralie Poncet, et al.
Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.
Journal of the National Cancer Institute|November 9, 2014
Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer researchMartine Moossdorff, Lori M van Roozendaal, Luc J A Strobbe, et al.
Lancet (London, England)|April 18, 2024
The Lancet Breast Cancer CommissionCharlotte E Coles, Helena Earl, Benjamin O Anderson, et al.
The New England Journal of Medicine|October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
The New England Journal of Medicine|June 6, 2022
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, William Jacot, Toshinari Yamashita, et al.
The Oncologist|February 5, 2014
A catalyst for change: the European cancer Patient's Bill of RightsMark Lawler, Thierry Le Chevalier, Martin J Murphy, et al.
JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Journal of the National Cancer Institute|October 18, 2024
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysisPer Karlsson, Anthony Fyles, S Laura Chang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO StudyNicholas C Turner, Judith Balmaña, Coralie Poncet, et al.
Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.
Journal of the National Cancer Institute|November 9, 2014
Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer researchMartine Moossdorff, Lori M van Roozendaal, Luc J A Strobbe, et al.
Lancet (London, England)|April 18, 2024
The Lancet Breast Cancer CommissionCharlotte E Coles, Helena Earl, Benjamin O Anderson, et al.
The New England Journal of Medicine|October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
The New England Journal of Medicine|June 6, 2022
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, William Jacot, Toshinari Yamashita, et al.
The Oncologist|February 5, 2014
A catalyst for change: the European cancer Patient's Bill of RightsMark Lawler, Thierry Le Chevalier, Martin J Murphy, et al.
JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
Pageof 14